Welcome, Guest. Please login or register.
June 22, 2024, 05:25:42 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55127
  • Total Topics: 4851
  • Online Today: 117
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 76
Total: 76


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA OKs AbbVie’s Mavyret for Adolescents With Hepatitis C  (Read 5315 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
FDA OKs AbbVie’s Mavyret for Adolescents With Hepatitis C
« on: August 05, 2019, 11:15:29 am »
The Food and Drug Administration (FDA) has approved AbbVie’s Mavyret (glecaprevir/pibrentasvir) to treat all six genotypes of hepatitis C virus (HCV) among adolescents.

Mavyret was approved to treat all genotypes of HCV among adults in August 2017.

The adolescent approval is based on clinical trials including 47 adolescents with genotype 1, 2, 3 or 4 of hep C who had no cirrhosis or only a mild case. All those who received the regimen for eight or 16 weeks achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).

For more....


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.